Navigation Links
ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
Date:5/5/2009

ADDISON, Texas, May 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal(TM) Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal(TM), was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance ("SALSA") at the University of Arizona College of Medicine, located in Tucson, Arizona.

The article is titled, "Use of a Nanoflex(TM) powder dressing for wound management following debridement for necrotizing fasciitis in the diabetic foot." The article details the treatment of a diabetic patient with a complex wound that requires multiple debridements and several different treatment modalities. The article reports that the patient was transitioned to Altrazeal(TM) following both negative pressure wound therapy and debridement of necrotic tissue. Observations in the article noted that the patient experienced decreased pain associated with wound dressing changes during weekly treatments using Altrazeal(TM), while new wound bed formed. During the treatment regimen, it was also noted that a large soft-tissue defect within the wound filled in with new granulating tissue while the Altrazeal(TM) dressing was pushed free of the hole.

Commenting on the publication, David Armstrong, DPM, PhD, co-author of the publication and Professor of Surgery and Director of SALSA stated, "We believe this technology to be potentially promising with a good deal of clinical versatility."

Renaat Van den Hooff, President and Chief Executive Officer of ULURU, commented: "We are pleased that the team at University of Arizona was the first to publish clinical evidence on the use of Altrazeal(TM) in a clinical setting. We believe this publication to be the first of many detailed scientific publications on Altrazeal(TM) used in clinical settings."

The citation for the publication is: Fitzgerald, R, Bharara, M, Mills, J, Armstrong, DG (2009); "Use of a Nanoflex(TM) powder dressing for wound management following debridement for necrotizing fasciitis in the diabetic foot" International Wound Journal, 6(2): 133-139. Requests for permission to reprint material from this journal should be addressed to:

    Journals Rights & Permissions Controller
    Blackwell Publishing
    9600 Garsington Road
    Oxford OX4 2DQ
    UK
    Email: JournalsRights@oxon.blackwellpublishing.com

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU, please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, patient comfort, pain management, ease of application, success in wound healing, and suitability of Altrazeal(TM) and Altrazeal(TM) Silver, the expectation that further scientific publications relating to Altrazeal(TM) will be published and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
2. ULURU Inc. (ULURU) Dealing Disclosure Requirements
3. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
5. ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
6. ULURU Inc. Announces Senior Management Change
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update
8. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
9. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
10. ULURU Inc. Announces Poster Presentations at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
11. ULURU Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: